The BioMedWire Podcast

AUSTIN, Texas, September 30, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.

To begin the interview, Durkacz discussed Quantum BioPharma’s lead drug candidate, Lucid-MS, and its differentiated approach to addressing multiple sclerosis.

“Lucid-MS is a drug that’s going to Phase 2. For the first time, this is going to be tested on patients with multiple sclerosis,” Durkacz said. “With MS, people start to lose control of their bodies. The reason is almost like a light bulb that starts flickering. The reason it’s flickering is because it’s connected by a copper wire with a plastic coating… The connectors from our brains have a protective coating as well, and that is called myelin. Lucid-MS is targeting myelin, which is totally different than every single drug today in the market for MS.”

Durkacz then explained why the upcoming Phase 2 trial represents an important milestone for the Lucid-MS development program.

“This is going to be the first time that patients with MS actually get to try Lucid-MS,” he said. “Phase 1 is done on healthy people… Phase 2 now allows us to test it on patients with MS, and we are looking very specifically for one thing: Does it help give them control back of their bodies? Because there is no drug in the world today that does that.”

Turning to unbuzzd™, Durkacz highlighted the product’s clinical results as well as Quantum BioPharma’s equity interest in the company behind it.

“unbuzzd™ is a powder that you put into water that is clinically proven to help you sober up from alcohol faster,” Durkacz said. “We published a peer-reviewed journal on the study in March of 2026, so people can go and actually see, and every single person tested in the study saw an increase in their blood alcohol metabolism rate… unbuzzd™ is going through an IPO process as we speak. When they go public and have raised money, they intend to do a full marketing launch of the product. Quantum BioPharma owns approximately 20% of unbuzzd™. We also have a royalty stream at 7% up to $250 million.”

Join IBN’s Carmel Fisher for a fresh conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he provides an update on the company’s Lucid-MS Phase 2 program, the development and commercial opportunity surrounding unbuzzd™, and the key milestones investors can watch for moving forward.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

To view Durkacz’s previous appearance on The BioMedWire Podcast, visit https://ibn.fm/EBAAZ

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline

About Quantum BioPharma Ltd. 

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. ("Unbuzzd") (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information, visit the company’s website at www.QuantumBioPharma.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.IBN.Ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

AUSTIN, Texas, September 30, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.

To begin the interview, Durkacz discussed Quantum BioPharma’s lead drug candidate, Lucid-MS, and its differentiated approach to addressing multiple sclerosis.

“Lucid-MS is a drug that’s going to Phase 2. For the first time, this is going to be tested on patients with multiple sclerosis,” Durkacz said. “With MS, people start to lose control of their bodies. The reason is almost like a light bulb that starts flickering. The reason it’s flickering is because it’s connected by a copper wire with a plastic coating… The connectors from our brains have a protective coating as well, and that is called myelin. Lucid-MS is targeting myelin, which is totally different than every single drug today in the market for MS.”

Durkacz then explained why the upcoming Phase 2 trial represents an important milestone for the Lucid-MS development program.

“This is going to be the first time that patients with MS actually get to try Lucid-MS,” he said. “Phase 1 is done on healthy people… Phase 2 now allows us to test it on patients with MS, and we are looking very specifically for one thing: Does it help give them control back of their bodies? Because there is no drug in the world today that does that.”

Turning to unbuzzd™, Durkacz highlighted the product’s clinical results as well as Quantum BioPharma’s equity interest in the company behind it.

“unbuzzd™ is a powder that you put into water that is clinically proven to help you sober up from alcohol faster,” Durkacz said. “We published a peer-reviewed journal on the study in March of 2026, so people can go and actually see, and every single person tested in the study saw an increase in their blood alcohol metabolism rate… unbuzzd™ is going through an IPO process as we speak. When they go public and have raised money, they intend to do a full marketing launch of the product. Quantum BioPharma owns approximately 20% of unbuzzd™. We also have a royalty stream at 7% up to $250 million.”

Join IBN’s Carmel Fisher for a fresh conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he provides an update on the company’s Lucid-MS Phase 2 program, the development and commercial opportunity surrounding unbuzzd™, and the key milestones investors can watch for moving forward.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

To view Durkacz’s previous appearance on The BioMedWire Podcast, visit https://ibn.fm/EBAAZ

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline

About Quantum BioPharma Ltd. 

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. ("Unbuzzd") (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information, visit the company’s website at www.QuantumBioPharma.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.IBN.Ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

AUSTIN, Texas, September 18, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions.

To begin the interview, Geller provided an overview of Regentis’ regenerative medicine platform and its lead product, GelrinC®, which is being developed to treat cartilage injuries in the knee.

“Our company, Regentis, is focused on developing technologies for regeneration of tissue, hence the name,” Geller said. “In our particular case, we have a platform from which we can develop a variety of applications. Currently, our lead product is called GelrinC®. Gelrin is the platform and C stands for cartilage, and we are specifically focused on treating cartilage injuries to the knee. We are already approved for marketing in Europe, and we are in the midst of our clinical trial, the pivotal trial which will get us permission from the FDA to start marketing in the U.S.”

Turning to the market opportunity, Geller discussed the prevalence of cartilage injuries among knee-related conditions and the size of the U.S. market Regentis is targeting.

“We believe that there are two layers to that market. The very obvious one: a patient comes to the doctor suffering from pain in his knee, and he would probably have one of three potential pathologies,” Geller said. “The major one, covering more than 50% of the cases, is ours. The total U.S. market annually is 470,000 cases a year, and that is the size of the market currently untreated.”

Looking at Regentis’ priorities for the remainder of 2026, Geller highlighted continued enrollment in the company’s U.S. pivotal study as well as efforts to advance commercialization in Europe.

“We want to finish enrolling the balance of our patients for the U.S. pivotal study, which we’re now running,” Geller said. “We’re in the midst of that study, and our team is right now opening more sites for a clinical study in the U.S. to speed up the enrollment, which we hope to finish by approximately the end of the year. Another thing that we’re doing is working quite actively on commercialization. We have approval in Europe, so we are permitted already to market and sell in Europe. Following our IPO, we started activities toward that. We are in discussion with a number of distribution systems and/or strategic major orthopedic companies in Europe.”

To close the interview, Dr. Geller said, “The message we bring to the market is one of a short, 10-minute procedure with two weeks of recovery, and I must say we've put in front of us durability as a slogan for the company. We need to treat patients in a way that will hold for a long time.”

Join IBN’s Stuart Smith for a conversation with Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials, as he further explores GelrinC®, the company’s U.S. pivotal study and European commercialization strategy, the market opportunity for cartilage repair, its broader regenerative medicine platform, intellectual property portfolio and key development and commercial milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

For more information, visit the company’s website at www.Regentis.co.il

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.IBN.Ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Corporate Communications

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

AUSTIN, Texas, September 18, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions.

To begin the interview, Geller provided an overview of Regentis’ regenerative medicine platform and its lead product, GelrinC®, which is being developed to treat cartilage injuries in the knee.

“Our company, Regentis, is focused on developing technologies for regeneration of tissue, hence the name,” Geller said. “In our particular case, we have a platform from which we can develop a variety of applications. Currently, our lead product is called GelrinC®. Gelrin is the platform and C stands for cartilage, and we are specifically focused on treating cartilage injuries to the knee. We are already approved for marketing in Europe, and we are in the midst of our clinical trial, the pivotal trial which will get us permission from the FDA to start marketing in the U.S.”

Turning to the market opportunity, Geller discussed the prevalence of cartilage injuries among knee-related conditions and the size of the U.S. market Regentis is targeting.

“We believe that there are two layers to that market. The very obvious one: a patient comes to the doctor suffering from pain in his knee, and he would probably have one of three potential pathologies,” Geller said. “The major one, covering more than 50% of the cases, is ours. The total U.S. market annually is 470,000 cases a year, and that is the size of the market currently untreated.”

Looking at Regentis’ priorities for the remainder of 2026, Geller highlighted continued enrollment in the company’s U.S. pivotal study as well as efforts to advance commercialization in Europe.

“We want to finish enrolling the balance of our patients for the U.S. pivotal study, which we’re now running,” Geller said. “We’re in the midst of that study, and our team is right now opening more sites for a clinical study in the U.S. to speed up the enrollment, which we hope to finish by approximately the end of the year. Another thing that we’re doing is working quite actively on commercialization. We have approval in Europe, so we are permitted already to market and sell in Europe. Following our IPO, we started activities toward that. We are in discussion with a number of distribution systems and/or strategic major orthopedic companies in Europe.”

To close the interview, Dr. Geller said, “The message we bring to the market is one of a short, 10-minute procedure with two weeks of recovery, and I must say we've put in front of us durability as a slogan for the company. We need to treat patients in a way that will hold for a long time.”

Join IBN’s Stuart Smith for a conversation with Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials, as he further explores GelrinC®, the company’s U.S. pivotal study and European commercialization strategy, the market opportunity for cartilage repair, its broader regenerative medicine platform, intellectual property portfolio and key development and commercial milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

For more information, visit the company’s website at www.Regentis.co.il

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.IBN.Ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Corporate Communications

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Disseminated on behalf of Onco-Innovations Ltd., may include paid advertisements.

AUSTIN, Texas, September 10, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF), a clinical-stage oncology company focused on advancing a new class of DNA Damage Response therapies and developing artificial intelligence-driven precision oncology solutions.

To begin the interview, Mohamed provided an overview of Onco-Innovations’ lead drug candidate, ONC010, and the company’s work targeting PNKP, a DNA repair enzyme that has not previously been targeted in a clinical-stage program.

“Onco-Innovations is a Canadian preclinical-stage precision oncology company. It’s headquartered in Calgary, and we’re developing a first-in-class DNA Damage Response inhibitor against a novel target,” Mohamed said. “That’s a DNA repair enzyme called polynucleotide kinase phosphatase, or PNKP. As far as we’re aware, there is no clinical-stage PNKP program anywhere in the world, and we hold exclusive worldwide rights to the University of Alberta’s foundational PNKP inhibitor patents together with an exclusive sublicense to the nanoparticle delivery platform that accompanies it.”

Disseminated on behalf of Onco-Innovations Ltd., may include paid advertisements.

AUSTIN, Texas, September 10, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF), a clinical-stage oncology company focused on advancing a new class of DNA Damage Response therapies and developing artificial intelligence-driven precision oncology solutions.

To begin the interview, Mohamed provided an overview of Onco-Innovations’ lead drug candidate, ONC010, and the company’s work targeting PNKP, a DNA repair enzyme that has not previously been targeted in a clinical-stage program.

“Onco-Innovations is a Canadian preclinical-stage precision oncology company. It’s headquartered in Calgary, and we’re developing a first-in-class DNA Damage Response inhibitor against a novel target,” Mohamed said. “That’s a DNA repair enzyme called polynucleotide kinase phosphatase, or PNKP. As far as we’re aware, there is no clinical-stage PNKP program anywhere in the world, and we hold exclusive worldwide rights to the University of Alberta’s foundational PNKP inhibitor patents together with an exclusive sublicense to the nanoparticle delivery platform that accompanies it.”

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development

and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN).

• What makes MS particularly devastating is its progressive nature.
• Rather than targeting the immune system, Quantum BioPharma’s Lucid-MS targets the myelin sheath.
• The case for Lucid-MS is grounded in more than a decade of rigorous science.
• Quantum BioPharma’s path to phase 2 has been methodical and deliberate.

To read the Full Publication, visit https://ibn.fm/wILk2

For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

 

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development

and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN).

• What makes MS particularly devastating is its progressive nature.
• Rather than targeting the immune system, Quantum BioPharma’s Lucid-MS targets the myelin sheath.
• The case for Lucid-MS is grounded in more than a decade of rigorous science.
• Quantum BioPharma’s path to phase 2 has been methodical and deliberate.

To read the Full Publication, visit https://ibn.fm/wILk2

For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

 

BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), (Profile) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX), that are focused on developing therapies for serious diseases, particularly cancer.

• PARP inhibitors transformed oncology when they arrived in the clinic more than a decade ago, but they are only one entry point into a complex biological system.
• Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology.
• The company’s preclinical program has produced specific, measurable results that support the biological rationale for PNKP inhibition in solid tumors.
• ONCO holds exclusive global rights across three distinct layers of protection, each reinforcing the others.

To read the Full Publication, visit https://ibn.fm/Lhc3W

For further information about Onco-Innovations, visit the Onco-Innovations profile.

 

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), (Profile) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX), that are focused on developing therapies for serious diseases, particularly cancer.

• PARP inhibitors transformed oncology when they arrived in the clinic more than a decade ago, but they are only one entry point into a complex biological system.
• Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology.
• The company’s preclinical program has produced specific, measurable results that support the biological rationale for PNKP inhibition in solid tumors.
• ONCO holds exclusive global rights across three distinct layers of protection, each reinforcing the others.

To read the Full Publication, visit https://ibn.fm/Lhc3W

For further information about Onco-Innovations, visit the Onco-Innovations profile.

 

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO),  Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone.

• Biotechnology companies are increasingly exploring alternative strategies focused on improving the performance of already-approved therapeutics.
• Oncotelic Therapeutics is advancing delivery-focused technologies intended to potentially improve exposure consistency and therapeutic performance.
• Nanotechnology-enabled drug delivery has emerged as one of the fastest-growing segments within oncology therapeutics.
• Oncotelic Therapeutics is pursuing an integrated platform strategy through both Deciparticle and PDAOAI, the company’s AI-enhanced biomedical infrastructure initiative.
• Investor attention across biotechnology is increasingly shifting toward companies developing differentiated platform technologies capable of supporting multiple drugs and therapeutic indications.

To read the full publication, visit: https://ibn.fm/KV2Tw

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO),  Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone.

• Biotechnology companies are increasingly exploring alternative strategies focused on improving the performance of already-approved therapeutics.
• Oncotelic Therapeutics is advancing delivery-focused technologies intended to potentially improve exposure consistency and therapeutic performance.
• Nanotechnology-enabled drug delivery has emerged as one of the fastest-growing segments within oncology therapeutics.
• Oncotelic Therapeutics is pursuing an integrated platform strategy through both Deciparticle and PDAOAI, the company’s AI-enhanced biomedical infrastructure initiative.
• Investor attention across biotechnology is increasingly shifting toward companies developing differentiated platform technologies capable of supporting multiple drugs and therapeutic indications.

To read the full publication, visit: https://ibn.fm/KV2Tw

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Disseminated on behalf of Quantum BioPharma, may include paid advertisements.

AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies.

To begin the interview, Durkacz outlined Quantum BioPharma’s primary focus on advancing its lead multiple sclerosis drug candidate, Lucid-MS.

“Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis,” he said. “If you know anybody that has the disease, you will see that over time there is a progression where they begin to lose control of parts of their body or sometimes their entire body. What our main drug candidate focus, Lucid-MS, is trying to do is reverse that damage that’s been done to people’s mobility. We believe that is something that is not addressed in any drug or therapy today in the world. There are almost three million people that suffer from this debilitating disease.”

Join IBN’s Stuart Smith for a conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he discusses the company’s Lucid-MS development program, its unbuzzd™ commercial strategy and the milestones ahead for 2026.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Disseminated on behalf of Quantum BioPharma, may include paid advertisements.

AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies.

To begin the interview, Durkacz outlined Quantum BioPharma’s primary focus on advancing its lead multiple sclerosis drug candidate, Lucid-MS.

“Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis,” he said. “If you know anybody that has the disease, you will see that over time there is a progression where they begin to lose control of parts of their body or sometimes their entire body. What our main drug candidate focus, Lucid-MS, is trying to do is reverse that damage that’s been done to people’s mobility. We believe that is something that is not addressed in any drug or therapy today in the world. There are almost three million people that suffer from this debilitating disease.”

Join IBN’s Stuart Smith for a conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he discusses the company’s Lucid-MS development program, its unbuzzd™ commercial strategy and the milestones ahead for 2026.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (“N2B”) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO).

• Oncotelic Therapeutics is focused on advancing technologies designed to bypass or overcome BBB limitations.
• The global burden of Alzheimer’s disease and related dementias is increasing at an unprecedented rate.
• Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security.
• As traditional drug-delivery approaches continue to face limitations, alternative methods designed to bypass the BBB, such as those being developed by Oncotelic, are gaining increasing attention.
• The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies.

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

 

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

 

BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (“N2B”) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO).

• Oncotelic Therapeutics is focused on advancing technologies designed to bypass or overcome BBB limitations.
• The global burden of Alzheimer’s disease and related dementias is increasing at an unprecedented rate.
• Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security.
• As traditional drug-delivery approaches continue to face limitations, alternative methods designed to bypass the BBB, such as those being developed by Oncotelic, are gaining increasing attention.
• The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies.

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

 

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

 

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE).

• As the global obesity crisis continues, GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine.
• SureNano Science is advancing GEP-44 as a next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs.
• The global GLP-1 market could total more than $200 billion by 2035 as patient adoption expands and broader therapeutic applications emerge.
• Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence.
• SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio, including exposure to Ibogaine.

For further information about SureNano Science Ltd., visit the SureNano Science profile.

 

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE).

• As the global obesity crisis continues, GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine.
• SureNano Science is advancing GEP-44 as a next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs.
• The global GLP-1 market could total more than $200 billion by 2035 as patient adoption expands and broader therapeutic applications emerge.
• Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence.
• SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio, including exposure to Ibogaine.

For further information about SureNano Science Ltd., visit the SureNano Science profile.

 

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com